Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8REJ

Crystal structure of PPAR gamma Ligand Binding Domain in complex with the ligand LBB78

Summary for 8REJ
Entry DOI10.2210/pdb8rej/pdb
DescriptorPeroxisome proliferator-activated receptor gamma, (2~{S})-2-(4-naphthalen-1-ylphenoxy)-3-phenyl-propanoic acid (3 entities in total)
Functional Keywordsnuclear receptors, ppars, transcription
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight69534.24
Authors
Capelli, D.,Montanari, R. (deposition date: 2023-12-11, release date: 2024-10-16)
Primary citationLaghezza, A.,Cerchia, C.,Genovese, M.,Montanari, R.,Capelli, D.,Wackerlig, J.,Simic, S.,Falbo, E.,Pecora, L.,Leuci, R.,Brunetti, L.,Piemontese, L.,Tortorella, P.,Biswas, A.,Singh, R.P.,Tambe, S.,Sudeep, C.A.,Pattnaik, A.K.,Jayaprakash, V.,Paoli, P.,Lavecchia, A.,Loiodice, F.
A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties.
Eur.J.Med.Chem., 275:116567-116567, 2024
Cited by
PubMed Abstract: New analogs of the PPAR pan agonist AL29-26 encompassed ligand (S)-7 showing potent activation of PPARα and -γ subtypes as a partial agonist. In vitro experiments and docking studies in the presence of PPAR antagonists were performed to help interpretation of biological data and investigate the main interactions at the binding sites. Further in vitro experiments showed that (S)-7 induced anti-steatotic effects and enhancement of the glucose uptake. This latter effect could be partially ascribed to a significant inhibition of the mitochondrial pyruvate carrier demonstrating that (S)-7 also acted through insulin-independent mechanisms. In vivo experiments showed that this compound reduced blood glucose and lipid levels in a diabetic mice model displaying no toxicity on bone, kidney, and liver. To our knowledge, this is the first example of dual PPARα/γ partial agonist showing these combined effects representing, therefore, the potential lead of new drugs for treatment of dyslipidemic type 2 diabetes.
PubMed: 38865743
DOI: 10.1016/j.ejmech.2024.116567
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.16 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon